Informed-money record
PALI · PALISADE BIO, INC.
Disclosed informed-money activity on this name over the last 12 months — corporate insiders, institutions, and members of Congress, from public-domain SEC and congressional filings. A dated factual record with receipts; interpretation is yours.
Bullish filings
8
Bearish filings
6
Named actors
4
Disclosed $ (bull / bear)
$268K / $832K
Recent disclosures
14 of 14 in the window · linked to source| Date | Who | What | Disclosed $ | Receipt |
|---|---|---|---|---|
| 2026-07-09 | Director Baltera Robert Jr. | bought | $49K | SEC ↗ |
| 2026-07-08 | Director Baltera Robert Jr. | bought | $40K | SEC ↗ |
| 2026-07-07 | CEO, CFO Finley John David | sold | $303K | SEC ↗ |
| 2026-07-07 | Chief Medical Officer Jones Mitchell Lawrence | sold | $107K | SEC ↗ |
| 2026-07-07 | Director Baltera Robert Jr. | bought | $61K | SEC ↗ |
| 2026-07-07 | Officer (via Raymond James & Associates) Finley John David | filed notice to sell | $303K | SEC ↗ |
| 2026-07-07 | Officer (via Raymond James & Associates) Jones Mitchell Lawrence | filed notice to sell | $108K | SEC ↗ |
| 2026-07-06 | Director Baltera Robert Jr. | bought | $41K | SEC ↗ |
| 2026-07-02 | Director Baltera Robert Jr. | bought | $20K | SEC ↗ |
| 2026-07-01 | Director Baltera Robert Jr. | bought | $40K | SEC ↗ |
| 2026-02-12 | CEO, CFO Finley John David | sold | $7K | SEC ↗ |
| 2026-02-12 | Chief Medical Officer Jones Mitchell Lawrence | sold | $3K | SEC ↗ |
| 2026-01-16 | Director Williams Donald Allen | bought | $8K | SEC ↗ |
| 2026-01-09 | Director Williams Donald Allen | bought | $9K | SEC ↗ |
Want the read, not just the record?
Members see how notable each move is, whether the actor's track record validates, cross-source convergence, and alerts on this name.
Create a free account →Dispute or correct this record
Events dated by when the activity occurred (a trade's transaction date; a notice, stake, or announcement at its filing date); the linked filing is the authoritative record. Directional public-domain disclosures only. Descriptive, not investment advice. Methodology · Today's notable signals